Cargando…

Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates

Intragenic deletion is the most common form of activating mutation among receptor tyrosine kinases (RTK) in glioblastoma. However, these events are not detected by conventional DNA sequencing methods commonly utilized for tumor genotyping. To comprehensively assess the frequency, distribution, and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastenhuber, Edward R., Huse, Jason T., Berman, Samuel H., Pedraza, Alicia, Zhang, Jianan, Suehara, Yoshiyuki, Viale, Agnes, Cavatore, Magali, Heguy, Adriana, Szerlip, Nicholas, Ladanyi, Marc, Brennan, Cameron W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984672/
https://www.ncbi.nlm.nih.gov/pubmed/24292886
http://dx.doi.org/10.1007/s00401-013-1217-3
_version_ 1782311464880570368
author Kastenhuber, Edward R.
Huse, Jason T.
Berman, Samuel H.
Pedraza, Alicia
Zhang, Jianan
Suehara, Yoshiyuki
Viale, Agnes
Cavatore, Magali
Heguy, Adriana
Szerlip, Nicholas
Ladanyi, Marc
Brennan, Cameron W.
author_facet Kastenhuber, Edward R.
Huse, Jason T.
Berman, Samuel H.
Pedraza, Alicia
Zhang, Jianan
Suehara, Yoshiyuki
Viale, Agnes
Cavatore, Magali
Heguy, Adriana
Szerlip, Nicholas
Ladanyi, Marc
Brennan, Cameron W.
author_sort Kastenhuber, Edward R.
collection PubMed
description Intragenic deletion is the most common form of activating mutation among receptor tyrosine kinases (RTK) in glioblastoma. However, these events are not detected by conventional DNA sequencing methods commonly utilized for tumor genotyping. To comprehensively assess the frequency, distribution, and expression levels of common RTK deletion mutants in glioblastoma, we analyzed RNA from a set of 192 glioblastoma samples from The Cancer Genome Atlas for the expression of EGFRvIII, EGFRvII, EGFRvV (carboxyl-terminal deletion), and PDGFRAΔ8,9. These mutations were detected in 24, 1.6, 4.7, and 1.6 % of cases, respectively. Overall, 29 % (55/189) of glioblastomas expressed at least one RTK intragenic deletion transcript in this panel. For EGFRvIII, samples were analyzed by both quantitative real-time PCR (QRT-PCR) and single mRNA molecule counting on the Nanostring nCounter platform. Nanostring proved to be highly sensitive, specific, and linear, with sensitivity comparable or exceeding that of RNA seq. We evaluated the prognostic significance and molecular correlates of RTK rearrangements. EGFRvIII was only detectable in tumors with focal amplification of the gene. Moreover, we found that EGFRvIII expression was not prognostic of poor outcome and that neither recurrent copy number alterations nor global changes in gene expression differentiate EGFRvIII-positive tumors from tumors with amplification of wild-type EGFR. The wide range of expression of mutant alleles and co-expression of multiple EGFR variants suggests that quantitative RNA-based clinical assays will be important for assessing the relative expression of intragenic deletions as therapeutic targets and/or candidate biomarkers. To this end, we demonstrate the performance of the Nanostring assay in RNA derived from routinely collected formalin-fixed paraffin-embedded tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-013-1217-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3984672
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-39846722014-04-23 Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates Kastenhuber, Edward R. Huse, Jason T. Berman, Samuel H. Pedraza, Alicia Zhang, Jianan Suehara, Yoshiyuki Viale, Agnes Cavatore, Magali Heguy, Adriana Szerlip, Nicholas Ladanyi, Marc Brennan, Cameron W. Acta Neuropathol Original Paper Intragenic deletion is the most common form of activating mutation among receptor tyrosine kinases (RTK) in glioblastoma. However, these events are not detected by conventional DNA sequencing methods commonly utilized for tumor genotyping. To comprehensively assess the frequency, distribution, and expression levels of common RTK deletion mutants in glioblastoma, we analyzed RNA from a set of 192 glioblastoma samples from The Cancer Genome Atlas for the expression of EGFRvIII, EGFRvII, EGFRvV (carboxyl-terminal deletion), and PDGFRAΔ8,9. These mutations were detected in 24, 1.6, 4.7, and 1.6 % of cases, respectively. Overall, 29 % (55/189) of glioblastomas expressed at least one RTK intragenic deletion transcript in this panel. For EGFRvIII, samples were analyzed by both quantitative real-time PCR (QRT-PCR) and single mRNA molecule counting on the Nanostring nCounter platform. Nanostring proved to be highly sensitive, specific, and linear, with sensitivity comparable or exceeding that of RNA seq. We evaluated the prognostic significance and molecular correlates of RTK rearrangements. EGFRvIII was only detectable in tumors with focal amplification of the gene. Moreover, we found that EGFRvIII expression was not prognostic of poor outcome and that neither recurrent copy number alterations nor global changes in gene expression differentiate EGFRvIII-positive tumors from tumors with amplification of wild-type EGFR. The wide range of expression of mutant alleles and co-expression of multiple EGFR variants suggests that quantitative RNA-based clinical assays will be important for assessing the relative expression of intragenic deletions as therapeutic targets and/or candidate biomarkers. To this end, we demonstrate the performance of the Nanostring assay in RNA derived from routinely collected formalin-fixed paraffin-embedded tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-013-1217-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2013-11-29 2014 /pmc/articles/PMC3984672/ /pubmed/24292886 http://dx.doi.org/10.1007/s00401-013-1217-3 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Kastenhuber, Edward R.
Huse, Jason T.
Berman, Samuel H.
Pedraza, Alicia
Zhang, Jianan
Suehara, Yoshiyuki
Viale, Agnes
Cavatore, Magali
Heguy, Adriana
Szerlip, Nicholas
Ladanyi, Marc
Brennan, Cameron W.
Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
title Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
title_full Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
title_fullStr Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
title_full_unstemmed Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
title_short Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
title_sort quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984672/
https://www.ncbi.nlm.nih.gov/pubmed/24292886
http://dx.doi.org/10.1007/s00401-013-1217-3
work_keys_str_mv AT kastenhuberedwardr quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT husejasont quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT bermansamuelh quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT pedrazaalicia quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT zhangjianan quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT sueharayoshiyuki quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT vialeagnes quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT cavatoremagali quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT heguyadriana quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT szerlipnicholas quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT ladanyimarc quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates
AT brennancameronw quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates